v3.25.2

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash	$ 4,315	$ 1,729
Other receivables	154	437
Prepaid expenses and other current assets	323	186
Total current assets	4,792	2,352
Property and equipment, net	50	85
Right-of-use assets - operating leases	581	670
Goodwill	2,044	2,044
Other assets	117	118
Total assets	7,584	5,269
Current liabilities:
Accounts payable	1,319	1,721
Accrued expenses	938	1,007
Income taxes payable	11	3
Operating lease liabilities, current	217	207
Contingent consideration liability, current	41
Other current liabilities	125
Total current liabilities	2,651	2,938
Warrant liabilities		1
Operating lease liabilities, non-current	376	477
Contingent consideration liability, non-current		41
Other liabilities	113	111
Total liabilities	3,140	3,568
Stockholders’ equity:
Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at June 30, 2025 and December 31, 2024, $156 liquidation preference	1	1
Common stock, $0.005 par value, 150,000 and 100,000 shares authorized at June 30, 2025 and December 31, 2024, respectively, 7,483 and 3,426 issued and outstanding at June 30, 2025 and December 31, 2024, respectively	37	17
Additional paid-in capital	247,291	233,219
Accumulated deficit	(242,885)	(231,536)
Total stockholders’ equity	4,444	1,701
Total liabilities and stockholders’ equity	$ 7,584	$ 5,269

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Ernexa Therapeutics Inc. 10-Q